HammadResearch.com

Research & Clinical Trials

Dr. Mustafa Hammad serves as founder and CEO of American NeuRegenix Institute (Stockbridge, Georgia, USA and Palestine) and a partner, Chair of the Institutional Review Board at Global Research Holdings, and leads investigator-initiated work conducted in collaboration with American NeuroSpine Center (ANSC). He has been a Certified Principal Investigator (CPI) since 2016.

Active Investigator-Led Programs (ANRI & ANSC)

  • Characterization of leukocyte-poor highly concentrated platelet-rich plasma (open double-spin protocol) — ANRI & ANSC.
  • Modified technique for reducing claustrophobia in cervical and brain MRI using lateral decubitus positioning (randomized controlled trial) — ANRI & ANSC.
  • MRI efficacy and safety post bone marrow–derived stem cell therapy for ACL tear — ANRI & ANSC.
  • Efficacy and safety of supraorbital, supratrochlear, auriculotemporal, and occipital nerve blocks with PRP in chronic migraine — prospective study — ANRI & ANSC.
  • Efficacy and safety of magnesium L-threonate in prevention of chronic migraine — prospective study — ANRI & ANSC.
  • Efficacy and safety of steroids versus PRP in epidural injections for lumbar disc disease — double-blinded study — ANRI & ANSC.
  • Efficacy and adverse events of PRP medial meniscus and intra-articular injections for medial meniscus tears and osteoarthritis — ANRI & ANSC.
  • Efficacy and safety of PRP spinoplasty in chronic lower back pain due to disc and facet pathology — ANRI & ANSC.
  • MRI efficacy and safety post non-surgical spinal decompression therapy — prospective study — ANRI & ANSC.

Selected Industry-Sponsored Trials (Principal Investigator)

  • Tezepelumab in severe uncontrolled asthma (Phase 3) — AstraZeneca.
  • Intravenous neridronic acid in complex regional pain syndrome — Syneos Health.
  • Lemborexant in insomnia disorder — Eisai.
  • Octagam 10% in dermatomyositis (ProDERM) — Octapharma.
  • Dalvance utilization registry (DRIVE) — Allergan.
  • Dalbavancin versus comparator in pediatric ABSSSI — Allergan.
  • Lemborexant in adults 55+ with insomnia — Eisai.
  • Pharmacogenomic test assessment in medication regimen — medical monitor role.
  • Levomilnacipran ER in adolescent major depressive disorder — Allergan.
  • ASCENT COPD (aclidinium cardiovascular safety) — AstraZeneca.
  • Extensively hydrolyzed casein formula allergy study — CliniPace.
  • Symbicort vs formoterol COPD exacerbation study.
  • Fingolimod PASSAGE safety cohort — Novartis.
  • Fingolimod TRANSITION from natalizumab — Novartis.
  • Acute ankle sprain pain efficacy study.
  • Renin inhibitor in type 2 diabetes with hypertension — Phase IIa.

Sub-Investigator & Early Career Highlights

  • Modified stem cells (SB623) in chronic motor deficit from ischemic stroke — SanBio.
  • Pediatric ADHD pharmacokinetic study.
  • Pediatric/adolescent excessive sleepiness in OSA.
  • Primary insomnia polysomnography studies.
  • Elderly chronic insomnia long-term safety.
  • Restless legs syndrome fixed-dose study.
  • ALS sensory abnormalities — principal investigator (Emory / SUNY era).
  • NBI-5788 (APL) in relapsing-remitting MS — Neuroscience Biosciences.
  • Betaseron weekly IM post-Avonex MS trial — Berlex.

Research Approach

  • Translational design linking biomarkers, imaging, and functional outcomes.
  • Rigorous safety monitoring and ethics/IRB alignment across geographies.
  • Practical endpoints that inform day-to-day neurology, pain, and sleep practice.
  • Openness to multicenter collaboration and sponsor feasibility dialogue.